Jazz Pharmaceuticals plc diskutieren
Jazz Pharmaceuticals plc
WKN: A1JS1K / Symbol: JAZZ / Name: Jazz Pharma / Aktie / Pharmazeutika / Mid Cap /
102,10 €
-1,40 %
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at Needham & Company LLC from $210.00 to $205.00. They now have a "buy" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $190.00 to $212.00. They now have a "buy" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $204.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $226.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at Royal Bank of Canada from $203.00 to $201.00. They now have an "outperform" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $204.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at Needham & Company LLC from $226.00 to $225.00. They now have a "buy" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at Royal Bank of Canada from $200.00 to $191.00. They now have an "outperform" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $225.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $200.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $160.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at Barclays PLC from $240.00 to $235.00. They now have an "overweight" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at Needham & Company LLC from $225.00 to $220.00. They now have a "buy" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at JPMorgan Chase & Co. from $180.00 to $170.00. They now have an "overweight" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $195.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $180.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at Barclays PLC from $235.00 to $230.00. They now have an "overweight" rating on the stock.
Ratings data for JAZZ provided by MarketBeat
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $220.00 price target on the stock.
Ratings data for JAZZ provided by MarketBeat
Neueste Beiträge
UBS_Group_AG in Energy Transfer LP diskutieren